Gasdermin E regulates the stability and activation of EGFR in human non-small cell lung cancer cells

[1]  S. Zhu,et al.  GSDME Is Related to Prognosis and Response to Chemotherapy in Oral Cancer , 2022, Journal of dental research.

[2]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[3]  M. Pagano,et al.  EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion , 2021, Cell.

[4]  Yuhuang Li,et al.  FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth , 2021, Nature Communications.

[5]  Oriol Vinyals,et al.  Highly accurate protein structure prediction with AlphaFold , 2021, Nature.

[6]  P. Vandenabeele,et al.  GSDME and its role in cancer: From behind the scenes to the front of the stage , 2020, International journal of cancer.

[7]  Fachao Zhi,et al.  HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway , 2020, Journal of Hematology & Oncology.

[8]  Xiaobin Wu,et al.  Exosome-Delivered LncHEIH Promotes Gastric Cancer Progression by Upregulating EZH2 and Stimulating Methylation of the GSDME Promoter , 2020, Frontiers in Cell and Developmental Biology.

[9]  Jin-jian Lu,et al.  Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth , 2020, Signal Transduction and Targeted Therapy.

[10]  Conrad C. Huang,et al.  UCSF ChimeraX: Structure visualization for researchers, educators, and developers , 2020, Protein science : a publication of the Protein Society.

[11]  J. Lieberman,et al.  Gasdermin E suppresses tumor growth by activating anti-tumor immunity , 2020, Nature.

[12]  Yingying Wang,et al.  Angio-associated migratory cell protein interacts with epidermal growth factor receptor and enhances proliferation and drug resistance in human non-small cell lung cancer cells. , 2019, Cellular signalling.

[13]  L. Lei,et al.  The role of pyroptosis in cancer: pro-cancer or pro-“host”? , 2019, Cell Death & Disease.

[14]  E. Alnemri,et al.  Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation , 2019, Nature Communications.

[15]  Pengfei Ma,et al.  Molecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell Death , 2018, Clinical Cancer Research.

[16]  G. Kiss,et al.  RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers , 2018, Nature Cell Biology.

[17]  S. Sigismund,et al.  Emerging functions of the EGFR in cancer , 2017, Molecular oncology.

[18]  Wenqing Gao,et al.  Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin , 2017, Nature.

[19]  Wenqing Gao,et al.  Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death. , 2017, Trends in biochemical sciences.

[20]  Dima Kozakov,et al.  The ClusPro web server for protein–protein docking , 2017, Nature Protocols.

[21]  E. Alnemri,et al.  Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death , 2017, Nature Communications.

[22]  Dacheng Wang,et al.  Pore-forming activity and structural autoinhibition of the gasdermin family , 2016, Nature.

[23]  K. Dwan,et al.  First-line treatment of advanced epidermal growth factor receptor ( EGFR ) mutation positive non-squamous non-small cell lung cancer Review information Review type : Intervention , 2015 .

[24]  Xiaojun Tan,et al.  Stress-Induced EGFR Trafficking: Mechanisms, Functions, and Therapeutic Implications. , 2016, Trends in cell biology.

[25]  R. Govindan,et al.  Genomic alterations in lung adenocarcinoma. , 2015, The Lancet. Oncology.

[26]  P. Poulikakos,et al.  Targeting RAS–ERK signalling in cancer: promises and challenges , 2014, Nature Reviews Drug Discovery.

[27]  Siew K. Yeap,et al.  Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation , 2014, Journal of medicinal chemistry.

[28]  J. Engelman,et al.  ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. , 2014, Cancer cell.

[29]  Mario Albrecht,et al.  Characterization of the EGFR interactome reveals associated protein complex networks and intracellular receptor dynamics , 2013, Proteomics.

[30]  Gur Pines,et al.  The ERBB network: at last, cancer therapy meets systems biology , 2012, Nature Reviews Cancer.

[31]  William Pao,et al.  Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer , 2010, Nature Reviews Cancer.

[32]  M. Toyota,et al.  Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer , 2010, Breast Cancer Research and Treatment.

[33]  J. Blenis,et al.  The RSK family of kinases: emerging roles in cellular signalling , 2008, Nature Reviews Molecular Cell Biology.

[34]  Guojun Wu,et al.  Aberrant promoter methylation and tumor suppressive activity of the DFNA5 gene in colorectal carcinoma , 2008, Oncogene.

[35]  J. Califano,et al.  Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancer. , 2008, Biochemical and biophysical research communications.

[36]  M. Toyota,et al.  Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer , 2007, Cancer science.

[37]  Xuejun Jiang,et al.  Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. , 2006, Molecular cell.

[38]  L. E. Johannessen,et al.  Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies , 2002, The Journal of cell biology.

[39]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[40]  Z. Kam,et al.  c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. , 1998, Genes & development.

[41]  G. Richardson,et al.  Nonsyndromic hearing impairment is associated with a mutation in DFNA5 , 1998, Nature Genetics.

[42]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..